ADAP - Adaptimmune Therapeutics plc Stock Trading

Adaptimmune Therapeutics (NASDAQ: ADAP ) has priced its public offering of 20.5M American Depositary Shares (“ADSs”) at $11.00/ADS, for expected gross proceeds of ~$225.5M. More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, , Read more ...

Shares of the clinical-stage biotech  Adaptimmune Therapeutics (NASDAQ: ADAP) fell by as much as 11% immediately out of the gate Monday morning. The drugmaker's stock kicked off the week off on a sour note thanks to a fairly large public offering consisting of 12.5 million of its America...

Edwards Lifesciences (NYSE: EW ) -66% . More news on: Edwards Lifesciences Corporation, Iterum Therapeutics plc, Novus Therapeutics, Inc., Stocks on the move, , Read more ...